US EditionPublished • loading... • Updated
"Great Excess Demand" when Alvotech Sold Convertible Bonds for 14 Billion
Summary by Vísir
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Alvotech has completed the sale of convertible bonds worth over $100 million, which comes as it becomes clear that the sale of the company's new drugs to the US market will be delayed, to a group of about twenty international investors, but the offering was said to be "significantly" oversubscribed. To hedge against market risk, a subsidiary of Alvotech is also selling the buyers of the bonds common shares in the biotech pharmaceutical company a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
